Alpha 2.0
Login Register
» Authors » Stephen P Kahanic

Stephen P Kahanic

Explore the profile of Stephen P Kahanic including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 6
Citations 577
Followers 0
Related Specialties
Oncology
General Medicine
Critical Care
Top 10 Co-Authors
Jeff A Sloan
Bart Barlogie
S Vincent Rajkumar
Brian G M Durie
Muneer H Abidi
Robert Z Orlowski
Christopher M Reynolds
Rachael Sexton
Charles L Loprinzi
Paul J Novotny
Published In
Support Care Cancer
Br J Cancer
Cancer
Lancet
J Clin Oncol
Affiliations
Soon will be listed here.
Recent Articles
1.
Longer term follow-up of the randomized phase III trial SWOG S0777: bortezomib, lenalidomide and dexamethasone vs. lenalidomide and dexamethasone in patients (Pts) with previously untreated multiple myeloma without an intent for immediate autologous...
Durie B, Hoering A, Sexton R, Abidi M, Epstein J, Rajkumar S, et al.
Blood Cancer J . 2020 May; 10(5):53. PMID: 32393732
SWOG S0777, a randomized phase III trial, compared bortezomib, lenalidomide and dexamethasone (VRd) with lenalidomide and dexamethasone (Rd). This updated analysis includes 460 patients evaluable for survival endpoints: 225 eligible...
2.
Bortezomib with lenalidomide and dexamethasone versus lenalidomide and dexamethasone alone in patients with newly diagnosed myeloma without intent for immediate autologous stem-cell transplant (SWOG S0777): a randomised, open-label, phase 3 trial
Durie B, Hoering A, Abidi M, Rajkumar S, Epstein J, Kahanic S, et al.
Lancet . 2016 Dec; 389(10068):519-527. PMID: 28017406
Background: Lenalidomide plus dexamethasone is a reference treatment for patients with newly diagnosed myeloma. The combination of the proteasome inhibitor bortezomib with lenalidomide and dexamethasone has shown significant efficacy in...
3.
Pilot trial of paclitaxel-trastuzumab adjuvant therapy for early stage breast cancer: a trial of the ECOG-ACRIN cancer research group (E2198)
Schneider B, ONeill A, Shen F, Sledge G, Thor A, Kahanic S, et al.
Br J Cancer . 2015 Dec; 113(12):1651-7. PMID: 26625004
Background: Blockade of human epidermal growth factor receptor type 2 (HER2) has dramatically improved outcome for patients with HER2-positive breast cancer. Trastuzumab, an anti-HER2 monoclonal antibody, has previously demonstrated improvement...
4.
Phase III, randomized study of the effects of parenteral iron, oral iron, or no iron supplementation on the erythropoietic response to darbepoetin alfa for patients with chemotherapy-associated anemia
Steensma D, Sloan J, Dakhil S, Dalton R, Kahanic S, Prager D, et al.
J Clin Oncol . 2010 Nov; 29(1):97-105. PMID: 21098317
Purpose: Functional iron deficiency may impair response to erythropoiesis-stimulating agents (ESAs) in iron-replete patients with chemotherapy-associated anemia (CAA). This study evaluated whether coadministration of parenteral iron improves ESA efficacy in...
5.
Tetracycline to prevent epidermal growth factor receptor inhibitor-induced skin rashes: results of a placebo-controlled trial from the North Central Cancer Treatment Group (N03CB)
Jatoi A, Rowland K, Sloan J, Gross H, Fishkin P, Kahanic S, et al.
Cancer . 2008 Jun; 113(4):847-53. PMID: 18543329
Background: Epidermal growth factor receptor (EGFR) inhibitors are effective cancer therapies, but they are reported to cause a rash in >50% of patients. In the current study, the authors examined...
6.
Donepezil and vitamin E for preventing cognitive dysfunction in small cell lung cancer patients: preliminary results and suggestions for future study designs
Jatoi A, Kahanic S, Frytak S, Schaefer P, Foote R, Sloan J, et al.
Support Care Cancer . 2004 Oct; 13(1):66-9. PMID: 15480814
Background: Up to 90% of small cell lung cancer (SCLC) patients suffer cognitive dysfunction. Since donepezil and vitamin E have been somewhat successful in treating other dementias, this study tested...